{"id":756,"date":"2026-07-11T07:06:56","date_gmt":"2026-07-11T07:06:56","guid":{"rendered":"https:\/\/valutednews.com\/?p=756"},"modified":"2026-07-11T07:06:56","modified_gmt":"2026-07-11T07:06:56","slug":"roche-eli-lilly-novo-gene-therapy-hansoh-readout-newsletter","status":"publish","type":"post","link":"https:\/\/valutednews.com\/?p=756","title":{"rendered":"Roche, Eli Lilly, Novo, gene therapy, Hansoh: Readout Newsletter"},"content":{"rendered":"
\"Roche,<\/div>

<\/p>\n

\n

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n

ARPA-H has unveiled a $160 million effort to speed bespoke gene-editing therapies for rare diseases into the clinic. Meanwhile, Roche has\u00a0abandoned two Huntington\u2019s gene-silencing drugs after disappointing data, and drugmakers have stepped in to promote Medicare\u2019s new obesity drug discount program.<\/p>\n

I got coffee with my cousin this morning here in SF. Before leaving for his job at an AI behemoth, he said the bone-chilling\u00a0July gloom is perfect \u201cworking weather.\u201d\u00a0<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a>
\n\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n

Already have an account? Log in<\/a><\/p>\n

\n
\n\t\t\t\t\t\t